CoChat

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer

Open access
Stenehjem, David, Tran, Dao, Nkrumah, Michael, Gupta, Shilpa · 2018 · OncoTargets and Therapy

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Until recently, systemic chemotherapy was the only option for treating bladder cancer and outcomes remained dismal. After a long gap of no progress for 40 years, immuno-therapy with checkpoint inhibitors (PDL1 and PD1) has revolutionized the treatment paradigm of bladder cancer, with five approved agents to treat platinum-refractory bladder cancer since the first approval of atezolizumab in May 2016. METHODS: This review summarizes the most recent data on approved checkpoint inhibitors currently used in management of advanced bladder cancer. Early- and late-phase trials of the five checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab) in advanced bladder cancer are reviewed in detail. This review also describes the potential application of PD1/PDL1 inhibitors in adjuvant and neoadjuvant settings and non-muscle-invasive bladder cancer, as well as with radiation in muscle-invasive bladder cancer treatment. The role of PDL1 and tumor-mutation burden and clinical considerations in choosing a particular immunotherapy are also discussed. RESULTS: The approved checkpoint inhibitors (PD1 and PDL1 inhibitors) have similar efficacy and safety profiles in metastatic platinum-refractory bladder cancer, but they vary in dose and frequency and cost burden. However, only pembrolizumab has shown superiority over standard chemotherapy in a randomized Phase III setting so far. In addition, in the first-line setting for cisplatin-ineligible patients, both pembrolizumab and atezolizumab are US Food and Drug Administration-approved and well tolerated. There is a lack of consensus on the utility of testing for PDL1 as a predictive biomarker, as patients with no PDL1 expression also derive some clinical benefit. Tumor-mutation burden is another predictive biomarker, but needs further validation. CONCLUSION: Immunotherapy has offered a glimmer of hope to patients with bladder cancer. The current landscape is rapidly evolving, with novel immunotherapy-combination trials to improve outcomes further and evaluate predictive biomarkers to help identify patients most likely to benefit from such therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ott.s135157

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Objective response rate of PD1/PDL1 inhibitors in the second-line setting. Notes: For each study, the objective response rate and 95% CI are provided in the total population (black circle) and by PDL1 expression above threshold (red upward triangle) and below threshold (blue downward triangles). Studies are ordered by PDL1 expression thresholds.
Figure 1 Objective response rate of PD1/PDL1 inhibitors in the second-line setting. Notes: For each study, the objective response rate and 95% CI are provided in the total population (black circle) and by PDL1 expression above threshold (red upward triangle) and below threshold (blue downward triangles). Studies are ordered by PDL1 expression thresholds.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

Items 101–144 of 144

Metadata

Authors
Stenehjem, D., Tran, D., Nkrumah, M., & Gupta, S.
Affiliations
University of Minnesota (US)
Corresponding author
Gupta, Shilpa
Venue
OncoTargets and Therapy
Published
2018-09
Volume
Volume 11
Pages
5973-5989
ISSN
1178-6930 (ISSN-L)
OpenAlex
W2890398072
Cited by
144
References
47
Citations by year
2026: 5 · 2025: 12 · 2024: 26 · 2023: 20 · 2022: 19 · 2021: 25 · 2020: 25 · 2019: 10 · 2018: 2
FWCI
3.45
Type
journal article
Language
en
Open access
Locations
  • OncoTargets and Therapy (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
Keywords
PD-1 inhibitors, PD-L1 inhibitors, bladder urothelial carcinoma, immune checkpoint inhibitors, pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab, adjuvant immunotherapy, neoadjuvant immunotherapy, non-muscle-invasive bladder cancer, muscle-invasive bladder cancer, radiotherapy, tumor mutational burden, predictive biomarkers, combination immunotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.